Suzhou Connect Reports Positive Results for Trial of Autoimmune Drug

Suzhou Connect Biopharma reported a successful Phase I study of CBP-307, its lead molecule and a drug candidate for several autoimmune diseases. The single ascending dose study assessed the tolerability, pharmacokinetics and pharmacodynamics of CBP-307. According to Connect, CBP-307 exhibited "highly potent" immune modulation activity at each level in a dose-dependent manner. The study was conducted by Connect's Australian subsidiary in Melbourne. More details.... Share this with colleagues: // //